c.papayannidis- harbor: a phase 2/3 study of blu-263 in patients with indolent systemic mastocytosis
Published 1 year ago • 45 plays • Length 6:15Download video MP4
Download video MP3
Similar videos
-
9:29
pioneer: avapritinib in patients with indolent systemic mastocytosis
-
2:26
cristina papayannidis tells about approach to ph-positive and ph-like all
-
2:07
avapritinib for indolent systemic mastocytosis
-
3:05
explorer: avapritinib in systemic mastocytosis
-
3:10
pioneer trial update: avapritinib for indolent systemic mastocytosis
-
5:14
avapritinib for indolent systemic mastocytosis in the pioneer trial
-
1:01:14
3-2-2023 - kit inhibition in systemic mastocytosis (a 20-year journey from patient zero)
-
12:48
cristina papayannidis - approach to ph-positive and ph-like all
-
4:35
clinical pearls in nonadvanced systemic mastocytosis
-
2:21
the efficacy of avapritinib to treat advanced systemic mastocytosis
-
6:03
ss18 hepatobiliary: s107 a-defensins and hscrp for comparing the inflammatory reaction
-
3:16
overview of systemic mastocytosis
-
1:00
complete remission seen in advanced systemic mastocytosis with avaritinib
-
7:24
hcrn gu 16-257: phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder s...
-
6:53
molecular simulations of the hla-e/β2m/peptide... - eva prašnikar - 3dsig - poster - ismb/eccb 2021
-
1:51
responses to avapritinib in patients with advanced systemic mastocytosis
-
6:41
cvi 2019_friday, 7/19_peripheral challenging case competition semifinals_naoki hayakawa, md
-
3:55
nr2f6 safeguarding against murine colitis